Corbus Pharmaceuticals Holdings, Inc. (CRBP): R&D Expense
$70.09M
Year ended 2025-12-31
$90.26M
Trailing 12 months to 2026-06-30
+63.2%
3-year compound annual growth
-6.5%
5-year compound annual growth
+28.1%
10-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $70.09M | +117.5% | 2026-03-09, From 2025-01-01 |
| 2024-12-31 | $32.22M | +3.4% | 2026-03-09, From 2024-01-01 |
| 2023-12-31 | $31.17M | +93.1% | 2025-03-11, From 2023-01-01 |
| 2022-12-31 | $16.14M | -55.7% | 2024-03-12, From 2022-01-01 |
| 2021-12-31 | $36.45M | -62.9% | 2023-03-07, From 2021-01-01 |
| 2020-12-31 | $98.27M | +9.7% | 2022-03-08, From 2020-01-01 |
| 2019-12-31 | $89.60M | +84.3% | 2021-03-15, From 2019-01-01 |
| 2018-12-31 | $48.61M | +86.7% | 2020-03-16, From 2018-01-01 |
| 2017-12-31 | $26.04M | +68.7% | 2019-03-12, From 2017-01-01 |
| 2016-12-31 | $15.44M | +162.1% | 2018-03-12, From 2016-01-01 |
| 2015-12-31 | $5.89M | +369.0% | 2018-03-12, From 2015-01-01 |
| 2014-12-31 | $1.26M | +496.0% | 2016-03-28, From 2014-01-01 |
| 2013-12-31 | $210.7K | n/a | 2015-02-10, From 2013-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | 2025-12-31 | $70.09M | +117.5% |
| Climb Bio, Inc. (CLYM) | 2025-12-31 | $46.71M | +225.8% |
| Eledon Pharmaceuticals, Inc. (ELDN) | 2025-12-31 | $66.27M | +27.5% |
| Gyre Therapeutics, Inc. (GYRE) | 2025-12-31 | $13.70M | +13.9% |
| Gossamer Bio, Inc. (GOSS) | 2025-12-31 | $174.09M | +25.7% |
| Apimeds Pharmaceuticals US, Inc. (APUS) | 2025-12-31 | $1.63M | n/a |
| Cypherpunk Technologies Inc. (CYPH) | 2025-12-31 | $25.67M | -55.1% |
| PepGen Inc. (PEPG) | 2025-12-31 | $71.04M | -7.1% |
| Transcode Therapeutics, Inc. (RNAZ) | 2025-12-31 | $13.42M | +38.3% |
Compare CRBP, CLYM, ELDN, GYRE side by side · Screen every company in Pharmaceutical Preparations ↗